Sun 2007.

Methods	Allocation: stratified randomisation according to hospitalisation order Blindness: open label Duration: 12 weeks
Participants	Diagnosis: schizophrenia (CCMD‐3), used at least two different types of typical antipsychotics, each treated for at least six weeks at the dosage of at least 500mg chlorpromazine equivalents per day, but no significant response; PANSS ≥ 60 History: duration of illness 7.4 ± 4.7 years n = 86 Sex: male and female Age: 26.7 ± 3.6 years
Interventions	1. Magnesium valproate + risperidol: valproate 250‐750 mg/d, mean dose 425 ± 195 mg/d; risperidol 2‐6 mg/d, mean dose 3.25 ± 1.85 mg/d; n = 42 2. Risperidol alone: 2‐6 mg/day, mean dose 3.25 ± 1.85 mg/day, n = 44
Outcomes	Neurocognitive tests: WAIS‐R, WMS, WCST Mental states: PANSS Adverse events Unable to use: Adverse events: TESS ‐ no data reported
Notes	We suspect randomisation of this study was not properly done as it is not clear how they did stratified randomisation according to hospitalisation order; we were unable to contact the study author to verify